Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bintrafusp alfa |
Synonyms | |
Therapy Description |
Bintrafusp alfa is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bintrafusp alfa | MSB0011359C|M7824 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 TGFBR2 Antibody 3 | Bintrafusp alfa is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03427411 | Phase II | Bintrafusp alfa | Phase II Trial of M7824 in Subjects With HPV Positive Malignancies | Completed | USA | 0 |
NCT02517398 | Phase I | Bintrafusp alfa | MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 3 |
NCT04727541 | Phase II | Bintrafusp alfa | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer (NEOBIL) | Terminated | DEU | 0 |
NCT04220775 | Phase Ib/II | Bintrafusp alfa | M7824 Plus Re-irradiation With Stereotactic Body Radiation Therapy for the Curative Intent Treatment of Recurrent Head and Neck Cancer | Terminated | USA | 0 |
NCT04489940 | Phase II | Bintrafusp alfa | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | Terminated | USA | ITA | FRA | ESP | BEL | 1 |
NCT03707587 | Phase II | Bintrafusp alfa | M7824 in People With Recurrent Respiratory Papillomatosis | Completed | USA | 0 |
NCT04501094 | Phase II | Bintrafusp alfa | A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma | Terminated | USA | 0 |
NCT03631706 | Phase II | Bintrafusp alfa Pembrolizumab | M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | Completed | USA | TUR | NLD | ITA | GRC | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 6 |
NCT03554473 | Phase Ib/II | Bintrafusp alfa + Topotecan Bintrafusp alfa + Temozolomide Bintrafusp alfa | M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers | Recruiting | USA | 0 |
NCT03436563 | Phase Ib/II | Bintrafusp alfa | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | Completed | USA | 0 |
NCT03840902 | Phase II | Carboplatin + Paclitaxel Bintrafusp alfa Cisplatin + Etoposide Durvalumab Bintrafusp alfa + Cisplatin + Etoposide Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | NLD | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 4 |
NCT04708067 | Phase I | Bintrafusp alfa | Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma | Active, not recruiting | USA | 0 |
NCT03620201 | Phase I | Bintrafusp alfa | M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer | Completed | USA | 0 |
NCT04246489 | Phase II | Bintrafusp alfa | Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | Completed | USA | HUN | FRA | ESP | BRA | BEL | AUS | ARG | 4 |
NCT05012098 | Phase II | Bintrafusp alfa | Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). | Completed | USA | 0 |
NCT04560686 | Phase II | Bintrafusp alfa | Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer | Terminated | USA | 0 |
NCT03833661 | Phase II | Bintrafusp alfa | M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) | Completed | USA | ITA | GBR | FRA | ESP | 4 |
NCT04417660 | Phase II | Bintrafusp alfa | Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma | Recruiting | USA | 0 |
NCT05005429 | Phase II | Bintrafusp alfa | Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (BIMES) | Completed | ESP | 0 |
NCT04349280 | Phase I | Bintrafusp alfa | A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer | Terminated | USA | NLD | FRA | ESP | CAN | 0 |
NCT04247282 | Phase Ib/II | Bintrafusp alfa Bintrafusp alfa + ETBX-011 + ETBX-051 + ETBX-061 Bintrafusp alfa + ETBX-011 + ETBX-051 + ETBX-061 + Nogapendekin alfa inbakicept | Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection | Completed | USA | 0 |
NCT04428047 | Phase II | Bintrafusp alfa | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma (ICING) | Terminated | FRA | 0 |